<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="11" family="Helvetica-Black,Bold" color="#ffffff"/>
	<fontspec id="font1" size="8" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font2" size="8" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font3" size="8" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font4" size="8" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font5" size="2" family="AkzidenzGroteskBE" color="#ffffff"/>
	<fontspec id="font6" size="15" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font7" size="16" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font8" size="12" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font9" size="6" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font10" size="8" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font11" size="11" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font12" size="9" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font13" size="9" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font14" size="9" family="SymbolMT" color="#000000"/>
	<fontspec id="font15" size="10" family="AkzidenzGroteskBE" color="#000000"/>
<text top="85" left="477" width="78" height="10" font="font0" id="p1_t1" reading_order_no="1" segment_no="1" tag_type="title">Open Access<a href="http://www.biomedcentral.com/info/about/charter/"><b>Open Access</b></a></text>
<text top="42" left="315" width="241" height="7" font="font1" id="p1_t2" reading_order_no="0" segment_no="0" tag_type="text">Available online http://breast-cancer-research.com/content/7/1/R19<b>Available online</b></text>
<text top="735" left="569" width="14" height="8" font="font4" id="p1_t3" reading_order_no="77" segment_no="23" tag_type="text">R19</text>
<text top="85" left="57" width="9" height="2" font="font5" id="p1_t4" reading_order_no="3" segment_no="2" tag_type="title">Vol 7 No 1</text>
<text top="85" left="57" width="103" height="14" font="font6" id="p1_t5" reading_order_no="2" segment_no="2" tag_type="title">Research article</text>
<text top="102" left="57" width="464" height="14" font="font7" id="p1_t6" reading_order_no="4" segment_no="3" tag_type="title">The p53-dependent apoptotic pathway of breast cancer cells</text>
<text top="120" left="57" width="434" height="14" font="font7" id="p1_t7" reading_order_no="5" segment_no="3" tag_type="title">(BC-M1) induced by the bis-type bioreductive compound<b>The p53-dependent apoptotic pathway of breast cancer cells </b></text>
<text top="138" left="57" width="196" height="14" font="font7" id="p1_t8" reading_order_no="6" segment_no="3" tag_type="title">aziridinylnaphthoquinone<b>(BC-M1) induced by the bis-type bioreductive compound </b></text>
<text top="155" left="57" width="421" height="12" font="font8" id="p1_t9" reading_order_no="7" segment_no="4" tag_type="text">Yu-Ping Yang 1 , Hsien-Shou Kuo 1 , Hsin-Da Tsai 1 , Yi-Chen Peng 1 and Yuh-Ling Lin 2<b>aziridinylnaphthoquinone</b></text>
<text top="189" left="57" width="308" height="7" font="font3" id="p1_t10" reading_order_no="8" segment_no="5" tag_type="text">1 Department of Biochemistry, College of Medicine, Taipei Medical University, Taiwan, ROC</text>
<text top="198" left="57" width="345" height="8" font="font3" id="p1_t11" reading_order_no="9" segment_no="6" tag_type="text">2 Department of Medicine, College of Medicine, Fu-Jen Catholic University, Taipei Hsien, Taiwan, ROC</text>
<text top="217" left="57" width="218" height="7" font="font3" id="p1_t12" reading_order_no="10" segment_no="7" tag_type="text">Corresponding author: Yuh-Ling Lin, med0018@mails.fju.edu.tw</text>
<text top="235" left="57" width="487" height="7" font="font3" id="p1_t13" reading_order_no="11" segment_no="8" tag_type="text">Received: 4 May 2004 Revisions requested: 27 May 2004 Revisions received: 4 Aug 2004 Accepted: 6 Sep 2004 Published: 04 Nov 2004</text>
<text top="253" left="57" width="253" height="7" font="font10" id="p1_t14" reading_order_no="12" segment_no="9" tag_type="text">Breast Cancer Res 2005, 7 :R19-R27 (DOI 10.1186/bcr939) http://breast-cancer-research.com/content/7/1/R19</text>
<text top="263" left="57" width="171" height="7" font="font3" id="p1_t15" reading_order_no="13" segment_no="10" tag_type="text">© 2004 Yang et al ., licensee BioMed Central Ltd.</text>
<text top="273" left="57" width="495" height="7" font="font3" id="p1_t16" reading_order_no="14" segment_no="11" tag_type="text">This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/</text>
<text top="283" left="57" width="397" height="7" font="font3" id="p1_t17" reading_order_no="15" segment_no="11" tag_type="text">2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is cited.</text>
<text top="313" left="57" width="43" height="10" font="font11" id="p1_t18" reading_order_no="16" segment_no="12" tag_type="title">Abstract</text>
<text top="333" left="57" width="240" height="8" font="font12" id="p1_t19" reading_order_no="17" segment_no="13" tag_type="text">Introduction Several aziridinylbenzoquinone drugs have</text>
<text top="344" left="57" width="240" height="8" font="font13" id="p1_t20" reading_order_no="18" segment_no="13" tag_type="text">undergone clinical trials as potential antitumor drugs. These</text>
<text top="354" left="57" width="240" height="8" font="font13" id="p1_t21" reading_order_no="19" segment_no="13" tag_type="text">bioreductive compounds are designed to kill cells preferentially</text>
<text top="365" left="57" width="240" height="8" font="font13" id="p1_t22" reading_order_no="20" segment_no="13" tag_type="text">within the hypoxia tumor microenvironment. The bioreductive</text>
<text top="375" left="57" width="240" height="8" font="font13" id="p1_t23" reading_order_no="21" segment_no="13" tag_type="text">compound of bis-type naphthoquinone synthesized in our</text>
<text top="386" left="57" width="240" height="8" font="font13" id="p1_t24" reading_order_no="22" segment_no="13" tag_type="text">laboratory, 2-aziridin-1-yl-3-[(2-{2-[(3-aziridin-1-yl-1,4-dioxo-1,4-</text>
<text top="396" left="57" width="233" height="8" font="font13" id="p1_t25" reading_order_no="23" segment_no="13" tag_type="text">dihydronaphthalen-2-yl)thio]ethoxy}ethyl)thio]naphthoquinone</text>
<text top="407" left="57" width="240" height="8" font="font13" id="p1_t26" reading_order_no="24" segment_no="13" tag_type="text">(AZ-1), had the most potent death effect on the breast cancer<i>Breast Cancer Res</i></text>
<text top="417" left="57" width="240" height="8" font="font13" id="p1_t27" reading_order_no="25" segment_no="13" tag_type="text">cells BC-M1 in our previous screening. In the present study, we</text>
<text top="428" left="57" width="240" height="8" font="font13" id="p1_t28" reading_order_no="26" segment_no="13" tag_type="text">determined that the mechanism of the death effect of BC-M1<b>7</b></text>
<text top="438" left="57" width="240" height="8" font="font13" id="p1_t29" reading_order_no="27" segment_no="13" tag_type="text">cells induced by AZ-1 was mediated by the apoptosis pathway.</text>
<text top="459" left="57" width="240" height="8" font="font12" id="p1_t30" reading_order_no="28" segment_no="15" tag_type="text">Methods We evaluated the cytotoxicity of AZ-1 and the anti-</text>
<text top="470" left="57" width="241" height="8" font="font13" id="p1_t31" reading_order_no="29" segment_no="15" tag_type="text">breast cancer drugs tamoxifen and paclitaxel to BC-M1 cells</text>
<text top="480" left="57" width="240" height="8" font="font13" id="p1_t32" reading_order_no="30" segment_no="15" tag_type="text">and MCF-7 cells by the MTT assay and measured the apoptosis<i> et al</i></text>
<text top="491" left="57" width="240" height="8" font="font13" id="p1_t33" reading_order_no="31" segment_no="15" tag_type="text">phenomena by Hoechst 33258 staining for apoptotic bodies.</text>
<text top="501" left="57" width="241" height="10" font="font13" id="p1_t34" reading_order_no="32" segment_no="15" tag_type="text">We also quantified the sub-G 1 peak area and the ratio of the<a href="http://creativecommons.org/licenses/by/2.0"> (http://creativecommons.org/licenses/by/</a></text>
<text top="512" left="57" width="240" height="10" font="font13" id="p1_t35" reading_order_no="33" segment_no="15" tag_type="text">CH 2 /CH 3 peak area of the cell membrane in BC-M1 cells by<a href="http://creativecommons.org/licenses/by/2.0">2.0),</a> which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is cited.</text>
<text top="522" left="57" width="190" height="8" font="font13" id="p1_t36" reading_order_no="34" segment_no="15" tag_type="text">flow cytometry and 1 H-NMR spectra, respectively.<b>Abstract</b></text>
<text top="533" left="57" width="240" height="8" font="font13" id="p1_t37" reading_order_no="35" segment_no="16" tag_type="text">The apoptosis-related protein expressions, including p53, p21,<b>Introduction</b></text>
<text top="544" left="57" width="240" height="8" font="font13" id="p1_t38" reading_order_no="36" segment_no="16" tag_type="text">the RNA-relating protein T-cell restricted intracellular antigen-</text>
<text top="556" left="57" width="240" height="8" font="font13" id="p1_t39" reading_order_no="37" segment_no="16" tag_type="text">related protein, cyclin-dependent kinase 2 (cell cycle regulating</text>
<text top="568" left="57" width="240" height="8" font="font13" id="p1_t40" reading_order_no="38" segment_no="16" tag_type="text">kinase) and pro-caspase 3, were detected by western blot, and</text>
<text top="580" left="57" width="240" height="8" font="font13" id="p1_t41" reading_order_no="39" segment_no="16" tag_type="text">the caspase-3 enzyme activity was also quantified by an assay</text>
<text top="591" left="57" width="11" height="8" font="font13" id="p1_t42" reading_order_no="40" segment_no="16" tag_type="text">kit.</text>
<text top="333" left="315" width="241" height="8" font="font12" id="p1_t43" reading_order_no="41" segment_no="14" tag_type="text">Results AZ-1 induced two of the breast cancer cell lines, with</text>
<text top="341" left="315" width="240" height="13" font="font13" id="p1_t44" reading_order_no="42" segment_no="14" tag_type="text">IC 50 = 0.51 µ M in BC-M1 cells and with IC 50 = 0.57 µ M in MCF-</text>
<text top="354" left="315" width="241" height="8" font="font13" id="p1_t45" reading_order_no="43" segment_no="14" tag_type="text">7 cells, and showed less cytotoxicity to normal fibroblast cells</text>
<text top="362" left="315" width="241" height="13" font="font13" id="p1_t46" reading_order_no="44" segment_no="14" tag_type="text">(skin fibroblasts) with IC 50 = 5.6 µ M. There was a 10-fold</text>
<text top="375" left="315" width="240" height="8" font="font13" id="p1_t47" reading_order_no="45" segment_no="14" tag_type="text">difference between two breast cancer cell lines and normal</text>
<text top="386" left="315" width="240" height="8" font="font13" id="p1_t48" reading_order_no="46" segment_no="14" tag_type="text">fibroblasts. Of the two anti-breast cancer drugs, tamoxifen</text>
<text top="393" left="315" width="241" height="13" font="font13" id="p1_t49" reading_order_no="47" segment_no="14" tag_type="text">showed IC 50 = 0.12 µ M to BC-M1 cells and paclitaxel had much<b>Methods</b></text>
<text top="407" left="315" width="240" height="8" font="font13" id="p1_t50" reading_order_no="48" segment_no="14" tag_type="text">less sensitivity than AZ-1. The expression of p53 protein</text>
<text top="414" left="315" width="240" height="11" font="font13" id="p1_t51" reading_order_no="49" segment_no="14" tag_type="text">increased from 0.5 to 1.0 µ M AZ-1 and decreased at 2.0 µ M</text>
<text top="425" left="315" width="241" height="11" font="font13" id="p1_t52" reading_order_no="50" segment_no="14" tag_type="text">AZ-1. The p21 protein increased from 0.5 µ M AZ-1, with the</text>
<text top="435" left="315" width="241" height="11" font="font13" id="p1_t53" reading_order_no="51" segment_no="14" tag_type="text">highest at 2 µ M AZ-1. Regarding the AZ-1 compound-induced</text>
<text top="449" left="315" width="240" height="8" font="font13" id="p1_t54" reading_order_no="52" segment_no="14" tag_type="text">BC-M1 cells mediating the apoptosis pathway, the apoptotic</text>
<text top="459" left="315" width="240" height="10" font="font13" id="p1_t55" reading_order_no="53" segment_no="14" tag_type="text">body formation, the sub-G 1 peak area, the ratio of CH 2 /CH 3 of</text>
<text top="470" left="315" width="240" height="8" font="font13" id="p1_t56" reading_order_no="54" segment_no="14" tag_type="text">phospholipids in the cell membrane and the enzyme activity of</text>
<text top="480" left="315" width="240" height="8" font="font13" id="p1_t57" reading_order_no="55" segment_no="14" tag_type="text">caspase-3 were all in direct proportion with the dose-dependent</text>
<text top="491" left="315" width="240" height="8" font="font13" id="p1_t58" reading_order_no="56" segment_no="14" tag_type="text">increase of the concentration of AZ-1. The death effect-related</text>
<text top="501" left="315" width="240" height="8" font="font13" id="p1_t59" reading_order_no="57" segment_no="14" tag_type="text">proteins, including T-cell restricted intracellular antigen-related</text>
<text top="512" left="315" width="240" height="8" font="font13" id="p1_t60" reading_order_no="58" segment_no="14" tag_type="text">protein, cyclin-dependent kinase 2, and pro-caspase-3, all dose-</text>
<text top="522" left="315" width="186" height="8" font="font13" id="p1_t61" reading_order_no="59" segment_no="14" tag_type="text">dependently decreased with AZ-1 concentration.</text>
<text top="554" left="315" width="241" height="8" font="font12" id="p1_t62" reading_order_no="60" segment_no="17" tag_type="text">Conclusions The AZ-1-induced cell death of BC-M1 cells</text>
<text top="564" left="315" width="241" height="8" font="font13" id="p1_t63" reading_order_no="61" segment_no="17" tag_type="text">mediating the apoptosis pathway might be associated with p53</text>
<text top="575" left="315" width="240" height="8" font="font13" id="p1_t64" reading_order_no="62" segment_no="17" tag_type="text">protein expression, and AZ-1 could have the chance to be a</text>
<text top="585" left="315" width="240" height="8" font="font13" id="p1_t65" reading_order_no="63" segment_no="17" tag_type="text">candidate drug for anti-breast cancer following more</text>
<text top="596" left="315" width="178" height="8" font="font13" id="p1_t66" reading_order_no="64" segment_no="17" tag_type="text">experimental evidence, such as animal models.</text>
<text top="617" left="57" width="415" height="7" font="font2" id="p1_t67" reading_order_no="65" segment_no="18" tag_type="text">Keywords: apoptosis, bioreductive compound, bis-type aziridinylnaphthoquinone, breast cancer cells (BC-M1 and MCF-7)</text>
<text top="656" left="57" width="64" height="10" font="font11" id="p1_t68" reading_order_no="66" segment_no="19" tag_type="title">Introduction</text>
<text top="668" left="57" width="240" height="9" font="font15" id="p1_t69" reading_order_no="67" segment_no="21" tag_type="text">The bioreductive drugs, aziridinylbenzoquinones, are a</text>
<text top="680" left="57" width="240" height="9" font="font15" id="p1_t70" reading_order_no="68" segment_no="21" tag_type="text">class of compounds designed to exploit one of the features</text>
<text top="691" left="57" width="240" height="9" font="font15" id="p1_t71" reading_order_no="69" segment_no="21" tag_type="text">of solid tumor biology caused by an inadequate blood sup-<b>Results</b></text>
<text top="656" left="315" width="241" height="9" font="font15" id="p1_t72" reading_order_no="70" segment_no="20" tag_type="text">ply to the solid tumor; namely, tumor hypoxia. Such regions</text>
<text top="668" left="315" width="240" height="9" font="font15" id="p1_t73" reading_order_no="71" segment_no="20" tag_type="text">generally are resistant to radiation and other oxygen-requir-</text>
<text top="680" left="315" width="240" height="9" font="font15" id="p1_t74" reading_order_no="72" segment_no="20" tag_type="text">ing treatment [1-4]. The ideal bioreductive drug should be</text>
<text top="691" left="315" width="240" height="9" font="font15" id="p1_t75" reading_order_no="73" segment_no="20" tag_type="text">administered as an inactive prodrug that is only activated</text>
<text top="714" left="57" width="496" height="7" font="font3" id="p1_t76" reading_order_no="74" segment_no="22" tag_type="footnote">AZ-1 = 2-aziridin-1-yl-3-[(2-{2-[(3-aziridin-1-yl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)thio]ethoxy}ethyl)thio]naphthoquinone; cdk = cyclin-dependent</text>
<text top="724" left="57" width="499" height="8" font="font3" id="p1_t77" reading_order_no="75" segment_no="22" tag_type="footnote">kinase; DMEM = Dulbecco's modified Eagle's medium; IC 50 = inhibition concentration of 50% cell growth; NMR = nuclear magnetic resonance; PBS</text>
<text top="733" left="57" width="300" height="7" font="font3" id="p1_t78" reading_order_no="76" segment_no="22" tag_type="footnote">= phosphate-buffered saline; TIAR = T-cell restricted intracellular antigen-related protein.</text>
</page>
</pdf2xml>
